BMS303141 | CAS#943962-47-8 | ATP citrate lyase inhibitor

MedKoo Cat#: 510276 | Name: BMS303141

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMS303141 is a potent inhibitor of ATP citrate lyase (ACL). BMS-303141 inhibits lipid synthesis in HepG2 cells with an IC50 of 8 μM, and lowers plasma triglycerides in a murine hyperlipdemia model.

Chemical Structure

BMS303141

CAS#943962-47-8

Theoretical Analysis

MedKoo Cat#: 510276

Name: BMS303141

CAS#: 943962-47-8

Chemical Formula: C19H15Cl2NO4S

Exact Mass: 423.0099

Molecular Weight: 424.30

Elemental Analysis: C, 53.78; H, 3.56; Cl, 16.71; N, 3.30; O, 15.08; S, 7.56

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,250.00	Ready to ship
500mg	USD 2,650.00	Ready to ship
1g	USD 3,650.00	Ready to ship
2g	USD 5,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

BMS303141; BMS-303141; BMS 303141.

IUPAC/Chemical Name

3,5-dichloro-2-hydroxy-N-(4-methoxy-[1,1'-biphenyl]-3-yl)benzenesulfonamide

InChi Key

SIIPNDKXZOTLEA-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H15Cl2NO4S/c1-26-17-8-7-13(12-5-3-2-4-6-12)9-16(17)22-27(24,25)18-11-14(20)10-15(21)19(18)23/h2-11,22-23H,1H3

SMILES Code

O=S(C1=CC(Cl)=CC(Cl)=C1O)(NC2=CC(C3=CC=CC=C3)=CC=C2OC)=O

Appearance

white to off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A21T09K17

QC Data

View QC data: current batch, Lot#A21T09K17

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 μM.

In vitro activity:

This study performed polyclonal activation of murine CD8+ T cells in vitro in the presence or absence of the Acly inhibitor BMS303141. This study found that inhibiting Acly during early activation results in decreased expression of early activation markers. Reference: Cytometry A. 2020 Dec 16. https://pubmed.ncbi.nlm.nih.gov/33325591/

In vivo activity:

BMS-303141 also suppressed osteoclast formation in vivo and prevents ovariectomy (OVX)-induced bone loss. Reference: J Bone Miner Res. 2021 Jun 22. doi: 10.1002/jbmr.4399. https://pubmed.ncbi.nlm.nih.gov/34155695/

	Solvent	mg/mL	mM
Solubility
	DMSO	53.6	126.23
	DMF	30.0	70.71
	DMF:PBS (pH 7.2) (1:1)	0.5	1.18
	Ethanol	18.1	42.68

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 424.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Guo Q, Kang H, Wang J, Dong Y, Peng R, Zhao H, Wu W, Guan H, Li F. Inhibition of ACLY Leads to Suppression of Osteoclast Differentiation and Function Via Regulation of Histone Acetylation. J Bone Miner Res. 2021 Jun 22. doi: 10.1002/jbmr.4399. Epub ahead of print. PMID: 34155695. 2. Vaughn N, Haviland DL. Acly promotes metabolic reprogramming and induction of IRF4 during early CD8+ T cell activation. Cytometry A. 2020 Dec 16. doi: 10.1002/cyto.a.24294. Epub ahead of print. PMID: 33325591. 3. Zheng Y, Zhou Q, Zhao C, Li J, Yu Z, Zhu Q. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis. J Cell Mol Med. 2021 Feb;25(3):1468-1479. doi: 10.1111/jcmm.16235. Epub 2021 Jan 3. PMID: 33393219; PMCID: PMC7875901.

In vitro protocol:

In vivo protocol:

1. Guo Q, Kang H, Wang J, Dong Y, Peng R, Zhao H, Wu W, Guan H, Li F. Inhibition of ACLY Leads to Suppression of Osteoclast Differentiation and Function Via Regulation of Histone Acetylation. J Bone Miner Res. 2021 Jun 22. doi: 10.1002/jbmr.4399. Epub ahead of print. PMID: 34155695. 2. Zheng Y, Zhou Q, Zhao C, Li J, Yu Z, Zhu Q. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis. J Cell Mol Med. 2021 Feb;25(3):1468-1479. doi: 10.1111/jcmm.16235. Epub 2021 Jan 3. PMID: 33393219; PMCID: PMC7875901.

1: Guo Q, Kang H, Wang J, Dong Y, Peng R, Zhao H, Wu W, Guan H, Li F. Inhibition of ACLY Leads to Suppression of Osteoclast Differentiation and Function Via Regulation of Histone Acetylation. J Bone Miner Res. 2021 Jun 22. doi: 10.1002/jbmr.4399. Epub ahead of print. PMID: 34155695. 2: Zheng Y, Zhou Q, Zhao C, Li J, Yu Z, Zhu Q. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis. J Cell Mol Med. 2021 Feb;25(3):1468-1479. doi: 10.1111/jcmm.16235. Epub 2021 Jan 3. PMID: 33393219; PMCID: PMC7875901. 3: Vaughn N, Haviland DL. Acly promotes metabolic reprogramming and induction of IRF4 during early CD8+ T cell activation. Cytometry A. 2021 Aug;99(8):825-831. doi: 10.1002/cyto.a.24294. Epub 2020 Dec 29. PMID: 33325591.